(Reuters Health) - Botox injections may be slightly better at reducing urinary incontinence in some older women than InterStim, an implanted bladder control device, results of a U.S. trial suggest.
Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...
Fecal incontinence can be an embarrassing condition, but those who suffer are not alone. According to The National Institute of Health’s Institute of Diabetes and Digestive and Kidney Diseases, nearly ...
Axonics has secured $40 million to support commercialization of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the end of a clinical trial ...
POMPANO BEACH, Fla.--(BUSINESS WIRE)--StimGuard, a privately-held, pre-commercial medical device company, today announced it is commencing a head-to-head study for its Chronic Affarent Nerve ...
The FDA has issued Medtronic clearance to market the InterStim sacral nerve stimulation therapy system for people with chronic fecal incontinence. The pacemaker-like device has already been FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results